Brief: Bolt Biotherapeutics Highlights Comprehensive Clinical Data From Phase 1 Dose-Escalation Trial Of Bdc-1001 As Monotherapy And In Combination With Nivolumab In Her2-Expressing Tumors At 2023 Asco Annual Meeting
25/05/2023 23:19
May 25 (Reuters) - Bolt Biotherapeutics Inc BOLT.O :
* BOLT BIOTHERAPEUTICS HIGHLIGHTS COMPREHENSIVE CLINICAL
DATA FROM
PHASE 1 DOSE-ESCALATION TRIAL OF BDC-1001 AS MONOTHERAPY AND IN
COMBINATION WITH NIVOLUMAB IN HER2-EXPRESSING TUMORS AT 2023
ASCO ANNUAL MEETING
Source text for Eikon: ID:nGNX9LMLdF
Further company coverage: BOLT.O
((Reuters.Briefs@thomsonreuters.com;))